Role of bacteria in experimental colitis
- PMID: 14507589
- DOI: 10.1016/s1521-6918(03)00068-4
Role of bacteria in experimental colitis
Abstract
Epidemiology suggests some relationship between the establishment of the gut flora and the risk of developing inflammatory bowel disease. Unrestrained activation of the immune system against commensal bacteria appears to be responsible for the chronicity of these diseases. In animal models, broad-spectrum antibiotics reduce the bacterial load and militate against intestinal inflammation. Several bacterial species found in of the common microflora, including anaerobes, are able to invade the colonic wall when there is dysfunction of the colonic mucosal barrier. Most aerobes provoke focal areas of acute inflammation, but some anaerobes in the predominant flora induce diffuse a fibrogenic transmural response. Current research aims to identify the probiotics that might act against these bacteria. Colonization with specific probiotic strains, including a bacterium genetically engineered to secrete interleukin-10, prevents spontaneous colitis in susceptible mice. Certain lactobacilli exhibit anti-inflammatory properties naturally, i.e. without previous genetic manipulation. Prebiotics may increase colonization by lactobacilli and can prevent mucosal inflammation. Modulation of the gut flora with probiotics may prove useful in the prevention and control of inflammatory bowel diseases.
Similar articles
-
Prebiotics in inflammatory bowel diseases.Br J Nutr. 2007 Oct;98 Suppl 1:S85-9. doi: 10.1017/S0007114507832958. Br J Nutr. 2007. PMID: 17922967 Review.
-
Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease.World J Gastroenterol. 2006 Jul 28;12(28):4452-60. doi: 10.3748/wjg.v12.i28.4452. World J Gastroenterol. 2006. PMID: 16874854 Free PMC article. Review.
-
Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats.Clin Diagn Lab Immunol. 2004 May;11(3):581-7. doi: 10.1128/CDLI.11.3.581-587.2004. Clin Diagn Lab Immunol. 2004. PMID: 15138186 Free PMC article.
-
Role of microecology in chronic inflammatory bowel diseases.Eur J Clin Nutr. 2002 Dec;56 Suppl 4:S34-8. doi: 10.1038/sj.ejcn.1601662. Eur J Clin Nutr. 2002. PMID: 12556945 Review.
-
The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics.Scand J Gastroenterol Suppl. 2001;(234):29-40. doi: 10.1080/003655201753265082. Scand J Gastroenterol Suppl. 2001. PMID: 11768558 Review.
Cited by
-
Intestinal Microbiota and Perspectives of the Use of Meta-Analysis for Comparison of Ulcerative Colitis Studies.J Clin Med. 2021 Jan 26;10(3):462. doi: 10.3390/jcm10030462. J Clin Med. 2021. PMID: 33530381 Free PMC article. Review.
-
Inflammatory Bowel Diseases: It's Time for the Adenosine System.Front Immunol. 2020 Jul 29;11:1310. doi: 10.3389/fimmu.2020.01310. eCollection 2020. Front Immunol. 2020. PMID: 32849492 Free PMC article. No abstract available.
-
A Labia Majora Sharing Perforator Flap for Labial Defect Reconstruction.Plast Reconstr Surg Glob Open. 2020 Jun 25;8(6):e2931. doi: 10.1097/GOX.0000000000002931. eCollection 2020 Jun. Plast Reconstr Surg Glob Open. 2020. PMID: 32766075 Free PMC article.
-
Lactobacillus paracasei Jlus66 extenuate oxidative stress and inflammation via regulation of intestinal flora in rats with non alcoholic fatty liver disease.Food Sci Nutr. 2019 Jul 15;7(8):2636-2646. doi: 10.1002/fsn3.1118. eCollection 2019 Aug. Food Sci Nutr. 2019. PMID: 31428351 Free PMC article.
-
The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.Pharmacol Rev. 2019 Jul;71(3):345-382. doi: 10.1124/pr.117.014878. Pharmacol Rev. 2019. PMID: 31235653 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
